References
- Sundkvist G MG, Ahlgren L, Lilja B, Mattsson S, Abrahamsson PA. Dynamic quantitative bone scintigraphy in patients with prostatic carcinoma treated by orchiectomy. Eur J Nucl Med 1990; 16: 671–6
- Citrin D L, Bessent R G, McGinley E, Gordon D. Dynamic studies with 99mTc-HEDP in normal subjects and in patients with bone tumors. J Nucl Med 1975; 16: 886–90
- Sundkvist G MG, Ahlgren L, Lilja B, Mattsson S, Abrahamsson P A, Wadström LB. Repeated quantitative bone scintigraphy in patients with prostatic carcinoma treated with orchiectomy. Eur J Nucl Med 1988; 14: 203–6
- Israel O, Front D, Frenkel A, Kleinhaus U. 24-hour/4-hour ratio of technetium-99m methylene diphosphonate uptake in patients with bone metastases and degenerative bone changes. J Nucl Med 1985; 26: 237–40
- Merrick M V, Ding C L, Chisholm G D, Elton RA. Prognostic significance of alkaline and acid phosphatase and skeletal scintigraphy in carcinoma of the prostate. Br J Urol 1985; 57: 715–20
- Paterson A HG. Bone metastases in breast cancer, prostate cancer and myeloma. Bone 1987; 8: 17–22, (Suppl 1)
- Fogelman I, Martin W. Assessment of skeletal uptake of 99mTc-diphosphonate over a five-day period. Eur J Nucl Med 1983; 8: 489–90
- Subramanian G, McAfee J G, Blair R J, Kallfelz F A, Thomas FD. Technetium-99m-methylene diphosphonate—A superior agent for skeletal imaging: Comparison with other technetium complexes. J Nucl Med 1975; 16: 744–55
- Blake G M, Zivanovic M A, McEwan A J, Ackery DM. Sr-89 therapy: Strontium kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med 1986; 12: 447–54
- Robinson R G, Blake G M, Preston DF, et al. Strontium-89: Treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone. Radio Graphics 1989; 9: 271–81
- Tennvall J, Darte L, Lundgren REl, Hassan AM. Palliation of multiple bone metastases from prostatic carcinoma with strontium-89. Acta Oncol 1988; 27: 365–9